Positively Aware Baraclude HBV


entecavir (ETV)

Nucleoside "Nuke"

Standard Dose

Adults (age 16 and older): Treatment-naïve with no resistance, one 0.5 mg tablet once daily. If lamivudine (Epivir) or telbivudine (Tyzeka, discontinued since December 2016) resistant, one 1 mg tablet once daily. Adults with decompensated liver disease (Child-Pugh B or C): one 1 mg tablet once daily. Baraclude should always be taken on an empty stomach (no food 2 hours before, or 2 hours after taking pill).

Dose adjustments needed for individuals with kidney disease (see chart below). Baraclude is safe to use in children ages 2 years and older, weighing at least 22 pounds (10 kg) or more. Dosing for children is based on weight and should be done in consultation with an experienced medical provider. An oral solution (0.05 mg/mL) is also available for children or as reduced doses in people with kidney disease.


Bristol-Myers Squibb


BRAND: 0.5 mg and 1 mg tablets—$1,647 / month
GENERIC: 0.5 mg and 1 mg tablets—$1,332–1,800 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information